Colloids Surf B Biointerfaces. 2025 Dec 23;260:115383. doi: 10.1016/j.colsurfb.2025.115383. Online ahead of print.
ABSTRACT
Coagulation dysfunction and bleeding control remain major challenges in trauma, surgery, and interventional therapy. Millions of patients die from excessive blood loss every year. Traditional hemostatic materials such as gelatin sponge, chitosan, and zeolite have limitations such as a single mechanism of action and poor biological stability. At the same time, clotting peptides have attracted much attention due to their low molecular weight, high biological activity, and precisely designed molecular structure. This paper systematically reviews the latest progress of coagulation peptides as a new hemostatic material, discusses their interaction mechanism with coagulation factors and platelet receptors, and analyzes the structural design strategy. Subsequently, this article critically analyzed the clinical trial data, efficacy comparison, and long-term safety evaluation of clotting peptides in the fields of gastrointestinal endoscopy, high-risk surgery, and systemic hemostasis. Finally, this article summarizes the key clinical translational barriers faced by the study of clotting peptides, including challenges such as long-term biocompatibility, potential thrombosis risks, and in vivo degradation characteristics. This review aims to provide systematic theoretical guidance and objective clinical transformation analysis for the rational design and performance optimization of a new generation of multifunctional coagulation peptide materials.
PMID:41455399 | DOI:10.1016/j.colsurfb.2025.115383